Bernhard Hellmich

Summary

Country: Germany

Publications

  1. ncbi [Rheumatology--searching for the individual therapeutic cocktail]
    B Hellmich
    , ,
    Dtsch Med Wochenschr 130:1555-8. 2005
  2. ncbi Advances in the therapy of Wegener's granulomatosis
    Bernhard Hellmich
    Department of Rheumatology, University Hospital of Schleswig Holstein, Campus Luebeck and Rheumaklinik Bad Bramstedt, Luebeck, Germany
    Curr Opin Rheumatol 18:25-32. 2006
  3. ncbi [Churg-Strauss syndrome--recent developments in diagnosis and treatment]
    B Hellmich
    Rheumaklinik Bad Bramstedt, , Rheumatologie und Immunologie, Bad Bramstedt
    Dtsch Med Wochenschr 131:2270-4. 2006
  4. ncbi Autoantibodies against granulocyte-macrophage colony stimulating factor and interleukin-3 are rare in patients with Felty's syndrome
    B Hellmich
    Poliklinik fur Rheumatologie, Universitatsklinikum Schleswig Holstein, Campus Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Ann Rheum Dis 63:862-6. 2004
  5. ncbi Update on the pathogenesis of Churg-Strauss syndrome
    B Hellmich
    Department of Rheumatology, University Hospital of Schleswig Holstein, Campus Lubeck, Germany
    Clin Exp Rheumatol 21:S69-77. 2003
  6. ncbi A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3
    B Hellmich
    Poliklinik fur Rheumatologie, Universitatsklinikum Schleswig Holstein, Campus Lübeck and Rheumaklinik Bad Bramstedt, Rheumaklinik Bad Bramstedt, Germany
    Clin Exp Rheumatol 25:S1-5. 2007
  7. ncbi [Polymyalgia rheumatica: myalgic syndrome or occult vasculitis?]
    B Hellmich
    Rheumaklinik Bad Bramstedt and Poliklinik für Rheumatologie, Universitatsklinikum Schleswig Holstein, Campus Lubeck
    Internist (Berl) 46:1233-43. 2005
  8. ncbi Recent progress in the pharmacotherapy of Churg-Strauss syndrome
    Bernhard Hellmich
    Poliklinik fur Rheumatologie, Universitatsklinikum Schleswig Holstein, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Expert Opin Pharmacother 5:25-35. 2004
  9. ncbi [Rheumatology -- Part 3. Research news concerning epidemiology, diagnosis, and therapy of primary systemic vasculitides]
    Peter Lamprecht
    , , ,
    Med Klin (Munich) 101:212-25. 2006
  10. ncbi Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study
    Elena Csernok
    Department of Rheumatology, University of Schleswig Holstein Campus Lübeck and Rheumaklinik Bad Bramstedt, Germany
    Rheumatology (Oxford) 43:174-80. 2004

Detail Information

Publications38

  1. ncbi [Rheumatology--searching for the individual therapeutic cocktail]
    B Hellmich
    , ,
    Dtsch Med Wochenschr 130:1555-8. 2005
  2. ncbi Advances in the therapy of Wegener's granulomatosis
    Bernhard Hellmich
    Department of Rheumatology, University Hospital of Schleswig Holstein, Campus Luebeck and Rheumaklinik Bad Bramstedt, Luebeck, Germany
    Curr Opin Rheumatol 18:25-32. 2006
    ..Results from several randomized controlled trials in patients with Wegener's granulomatosis and other antineutrophil cytoplasm antibody-associated vasculitides have recently been reported that have a great impact on patient care...
  3. ncbi [Churg-Strauss syndrome--recent developments in diagnosis and treatment]
    B Hellmich
    Rheumaklinik Bad Bramstedt, , Rheumatologie und Immunologie, Bad Bramstedt
    Dtsch Med Wochenschr 131:2270-4. 2006
  4. ncbi Autoantibodies against granulocyte-macrophage colony stimulating factor and interleukin-3 are rare in patients with Felty's syndrome
    B Hellmich
    Poliklinik fur Rheumatologie, Universitatsklinikum Schleswig Holstein, Campus Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Ann Rheum Dis 63:862-6. 2004
    ..In this study, we examined the prevalence of antibodies against two other granulopoietic cytokines: granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-3 (IL3)...
  5. ncbi Update on the pathogenesis of Churg-Strauss syndrome
    B Hellmich
    Department of Rheumatology, University Hospital of Schleswig Holstein, Campus Lubeck, Germany
    Clin Exp Rheumatol 21:S69-77. 2003
    ....
  6. ncbi A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3
    B Hellmich
    Poliklinik fur Rheumatologie, Universitatsklinikum Schleswig Holstein, Campus Lübeck and Rheumaklinik Bad Bramstedt, Rheumaklinik Bad Bramstedt, Germany
    Clin Exp Rheumatol 25:S1-5. 2007
    ..This study was designed to evaluate a novel ELISA method for detection of ANCA against proteinase-3 (PR3) for the diagnosis of Wegener's granulomatosis (WG) using PR3 presented in its native form...
  7. ncbi [Polymyalgia rheumatica: myalgic syndrome or occult vasculitis?]
    B Hellmich
    Rheumaklinik Bad Bramstedt and Poliklinik für Rheumatologie, Universitatsklinikum Schleswig Holstein, Campus Lubeck
    Internist (Berl) 46:1233-43. 2005
    ..Typical for PMR is the rapid response to corticosteroids. Usually the therapy needs to be continued for at least 2 years. Due to adverse events in many cases a corticosteroid saving therapy like methotrexate is needed...
  8. ncbi Recent progress in the pharmacotherapy of Churg-Strauss syndrome
    Bernhard Hellmich
    Poliklinik fur Rheumatologie, Universitatsklinikum Schleswig Holstein, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Expert Opin Pharmacother 5:25-35. 2004
    ..As relapses occur in > 25% of all patients, studies addressing the prevention of relapses in CSS are highly desirable in the future...
  9. ncbi [Rheumatology -- Part 3. Research news concerning epidemiology, diagnosis, and therapy of primary systemic vasculitides]
    Peter Lamprecht
    , , ,
    Med Klin (Munich) 101:212-25. 2006
    ..Biologicals play an increasing role in the treatment of refractory vasculitis...
  10. ncbi Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study
    Elena Csernok
    Department of Rheumatology, University of Schleswig Holstein Campus Lübeck and Rheumaklinik Bad Bramstedt, Germany
    Rheumatology (Oxford) 43:174-80. 2004
    ..To evaluate the performance characteristics of direct and capture ELISA for the detection of PR3-ANCA in Wegener's granulomatosis (WG) in international ANCA reference laboratories...
  11. ncbi Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway
    Elena Csernok
    Department of Rheumatology, University Hospital of Schleswig Holstein, Campus Lubeck, Germany
    Blood 107:4440-8. 2006
    ..Wegener autoantigen interacts with a "gateway" receptor (PAR-2) on iDCs in vitro triggering their maturation and licenses them for a T helper 1 (Th1)-type response potentially favoring granuloma formation in WG...
  12. ncbi EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis
    Bernhard Hellmich
    Department of Rheumatology, University Hospital of Schleswig Holstein, Campus Lubeck, Lubeck, Germany
    Ann Rheum Dis 66:605-17. 2007
    ..To develop the European League Against Rheumatism (EULAR) recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis...
  13. ncbi Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?
    Peer Malte Aries
    Department of Rheumatology, University Hospital of Schleswig Holstein, Campus Luebeck, Luebeck, Germany
    Clin Rev Allergy Immunol 29:237-45. 2005
    ..In conclusion, KD and AAV are the only vasculitides with a definite beneficial use of IVIg. For other vasculitides, the efficacy of IVIg has not been proven properly but may be useful in single cases...
  14. ncbi Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis
    C Metzler
    Department of Rheumatology, University Hospital of Schleswig Holstein, Campus Luebeck, Ratzeburger Allee 160, D 23538 Luebeck, Germany
    Rheumatology (Oxford) 46:1087-91. 2007
    ..Results from open-label trials suggest that methotrexate (MTX) and leflunomide (LEF) are effective for maintenance of remission in Wegener's granulomatosis (WG), but data from randomized controlled clinical trails are not yet available...
  15. ncbi [Rheumatology-part 2. Research news concerning pathogenesis, epidemiology, diagnosis, and therapy of connective tissue disease]
    Keihan Ahmadi-Simab
    Poliklinik fur Rheumatologie, Universitätsklinikum Schleswig Holstein Campus Lübeck, Ratzeburger Allee 160, 23538 Lubeck
    Med Klin (Munich) 101:127-37. 2006
    ..The current state of research in the field of collagen vascular diseases with its clinical consequences is reviewed in this article on the basis of the most recent data available...
  16. ncbi [Hypereosinophilic syndrome--recent developments in diagnosis and treatment]
    B Hellmich
    Rheumaklinik Bad Bramstedt, Abteilung fur Innere Medizin, Rheumatologie und Immunologie, Bad Bramstedt, und Poliklinik für Rheumatologie, Universitatsklinikum Schleswig Holstein, Campus Lubeck, Lubeck, Germany
    Dtsch Med Wochenschr 132:1892-6. 2007
    ....
  17. ncbi [Diagnosis und therapy of ANCA-associated vasculitis]
    P M Aries
    Poliklinik fur Rheumatologie, Universitatsklinikum Schleswig Holstein, Campus Lübeck und Rheumaklinik Bad Bramstedt
    Dtsch Med Wochenschr 131:443-6. 2006
    ..The introduction of a stage-adapted treatment has contributed to a significant improvement of the long-time prognosis of patients with AAV...
  18. ncbi Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment
    C Metzler
    Poliklinik fur Rheumatologie, Universitatsklinikum Schleswig Holstein, Campus Lübeck and Rheumaklinik Bad Bramstedt GmbH, Lubeck, Germany
    Clin Exp Rheumatol 22:S52-61. 2004
    ..To examine the safety and efficacy of methotrexate (MTX) plus low-dose prednisolone for induction of remission in non life- or organ-threatening courses and for remission maintenance in Churg-Strauss syndrome (CSS)...
  19. ncbi [Finger first white, then blue, finally red. How to recognize and treat Raynaud disease]
    K Ahmadi-Simab
    , ,
    MMW Fortschr Med 148:55-6. 2006
  20. ncbi [Glucocorticoids: importance in the treatment of vasculitis]
    P M Aries
    Universitatsklinikum Schleswig Holstein, Campus Lübeck und Rheumaklinik Bad Bramstedt, Oskar Alexander Strasse 26, 24576 Bad Bramstedt, Germany
    Z Rheumatol 64:155-61. 2005
    ..This article gives a short review of the present data of the role of GC in the treatment of vasculitis...
  21. ncbi Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations
    P M Aries
    University Hospital Schleswig Holstein, Campus Luebeck, Department of Rheumatology and Rheumaklinik Bad Bramstedt, Germany
    Ann Rheum Dis 65:853-8. 2006
    ..To investigate the safety and efficacy of rituximab (RTX) in patients with refractory Wegener's granulomatosis (WG)...
  22. ncbi Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease
    K Ahmadi-Simab
    Department of Rheumatology, University Hospital of Schleswig Holstein, Campus Lübeck and Rheumaklinik Bad Bramstedt, Germany
    Eur J Clin Invest 36:44-8. 2006
    ..ET is believed to be a key pathogenic mediator in systemic sclerosis (scleroderma, SSc), causing fibrotic, hypertrophic and inflammatory processes. PAH is one of the resulting deleterious effects in approximately 15% of SSc patients...
  23. ncbi Difficult to diagnose manifestations of vasculitis: does an interdisciplinary approach help?
    Bernhard Hellmich
    Department of Rheumatology, Poliklinik fur Rheumatologie, Universitätsklinfikum Schleswig Holstein, Campus Lübeck and Rheumaklinik Bad Bramstedt, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Best Pract Res Clin Rheumatol 19:243-61. 2005
    ..These two examples of difficult to diagnose manifestations of vasculitis illustrate the necessity of an interdisciplinary approach to the diagnostic work-up...
  24. ncbi New clues to accrue on neutropenia in rheumatoid arthritis
    Bernhard Hellmich
    , , , Germany
    Clin Immunol 117:1-5. 2005
  25. ncbi Variations in performance characteristics of commercial enzyme immunoassay kits for detection of antineutrophil cytoplasmic antibodies: what is the optimal cut off?
    J U Holle
    Department of Rheumatology, , Germany
    Ann Rheum Dis 64:1773-9. 2005
    ..Comparative analyses using sera from well characterised patients may help identify optimum cut off levels of commercial ANCA ELISA tests, resulting in better comparability of results among assays from different manufacturers...
  26. ncbi Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome
    B Hellmich
    , , , Ratzeburger Allee 160, , Germany
    Ann N Y Acad Sci 1051:121-31. 2005
    ..Although the association of ANCAs with CSS point toward an autoimmune origin of the disease, there is no direct evidence as yet for a direct pathogenic role of ANCAs in CSS...
  27. ncbi Low Fcgamma receptor III and high granulocyte colony-stimulating factor serum levels correlate with the risk of infection in neutropenia due to Felty's syndrome or systemic lupus erythematosus
    Bernhard Hellmich
    Poliklinik fur Rheumatologie, Medizinische Universitat zu Lubeck, Germany
    Am J Med 113:134-9. 2002
    ....
  28. ncbi The Annual European Congress of Rheumatology: recent advances in the treatment of rheumatic diseases. Lisbon, Portugal, June 18-21, 2003
    Bernhard Hellmich
    Poliklinik für Rheumatologie and Rheumaklinik Bad Bramstedt, Universitatsklinikum Schleswig Holstein, Campus Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Expert Opin Investig Drugs 12:1713-9. 2003
    ....
  29. ncbi [New therapeutic concepts for vasculitis and collagenosis]
    C Metzler
    , , , Ratzeburger Allee 160,
    Internist (Berl) 46:1347-53. 2005
    ..Recent experiences with Infliximab, Mycophenolate Mofetil, Rituximab und Deoxyspergualin for the treatment of the small vessel vasculitides and systemic lupus erythematosus are reviewed...
  30. ncbi Interstitial lung disease in polymyositis and dermatomyositis
    Armin Schnabel
    , , Ratzeburger Allee 160, , Germany
    Curr Rheumatol Rep 7:99-105. 2005
    ..Other immunosuppressants may be of benefit as well, but the weight of the current evidence supports the use of cyclophosphamide first...
  31. ncbi 20 years with ANCA (antineutrophil cytoplasmic autoantibodies): from seromarker to a major pathogenic player in vasculitis
    Bernhard Hellmich
    J Leukoc Biol 74:1-2. 2003
  32. ncbi Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies
    Richard Watts
    Department of Rheumatology, Ipswich Hospital NHS Trust, Heath Road, Ipswich IP4 5PD, UK
    Ann Rheum Dis 66:222-7. 2007
    ..Aim: To develop a consensus method of using these criteria and definitions for epidemiological studies to permit comparison without confounding by classification...
  33. ncbi Rapid immunodiagnosis of tuberculosis in a woman receiving anti-TNF therapy
    Christoph Lange
    Medical Clinic, and Division of Clinical Infectious Diseases, Research Center Borstel, Germany
    Nat Clin Pract Rheumatol 3:528-34. 2007
    ..The patient had begun treatment with bi-weekly subcutaneous injections of adalimumab 5 weeks earlier...
  34. ncbi Outpatient assessment of systemic vasculitis
    Anjali Nataraja
    Department of Rheumatology, Poole Hospital, Poole, UK
    Best Pract Res Clin Rheumatol 21:713-32. 2007
    ..Above all, however, it is very important to review these patients regularly and see them urgently in case of flares or complications, which are a common problem in most forms of vasculitis...
  35. ncbi The future of damage assessment in vasculitis
    Philip Seo
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Rheumatol 34:1357-71. 2007
    ..This initiative is part of a larger international effort to create a unified approach to disease assessment for the primary systemic vasculitides...
  36. ncbi Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus
    Bernhard Hellmich
    Medizinische Universitat zu Lubeck, Lubeck, Germany
    Arthritis Rheum 46:2384-91. 2002
    ....
  37. ncbi Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7
    Peter A Merkel
    Boston University School of Medicine, Boston, MA 02118, USA
    J Rheumatol 32:2488-95. 2005
    ....
  38. ncbi The PTPN22 620W allele is a risk factor for Wegener's granulomatosis
    Peter Jagiello
    Ruhr University, Bochum, Germany
    Arthritis Rheum 52:4039-43. 2005
    ..This study therefore examined whether the functionally relevant PTPN22 polymorphism is associated with Wegener's granulomatosis (WG)...